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Abstract
Adiponectin is an adipocytokine, and it plays a role in atherosclerosis. The role of adiponectin in the development of ischaemic stroke 
is controversial. Up to now, adiponectin was not evaluated in transient ischaemic stroke. In this study, we investigated the relationship 
between adiponectin and transient ischaemic attack. Forty patients with transient ischaemic attack were included into the study. In all 
patients, traditional risk factors of ischaemic stroke and intima-media thickness of carotid arteries were determined. Also, the relation-
ship between these parameters and adiponectin levels were examined. No difference was found in terms of adiponectin levels between 
patients and healthy subjects. In addition, there was no association between adiponectin levels and traditional risk factors. Our results 
suggest that adiponectin may not be a predictive risk factor of transient ischaemic attack.  (Endokrynol Pol 2015; 66 (3): 214–218)
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Streszczenie
Adiponektyna jest adipocytokiną i odgrywa ważną rolę w przebiegu miażdżycy. Jej rola w rozwoju udaru niedokrwiennego budzi 
kontrowersje. Aż do dziś nie oceniono działania adiponektyny w przemijających udarach niedokrwiennych. W niniejszym badaniu 
prześledzono związek adiponektyny z przemijającymi atakami niedokrwiennymi. Do badania włączono 40 pacjentów cierpiących na 
przemijające niedokrwienie mózgu. U wszystkich pacjentów wykryto typowe czynniki ryzyka udaru niedokrwiennego oraz zmiany 
w błonie środkowej i wewnętrznej tętnicy szyjnej. Zbadano także związek między tymi parametrami i stężeniem adiponektyny. Nie 
znaleziono różnic w poziomie adiponektyny między pacjentami oraz osobami zdrowymi. Dodatkowo, nie wykryto związku między 
stężeniem adiponektyny i typowymi czynnikami ryzyka. Wyniki badania sugerują, że adiponektyna może nie być czynnikiem ryzyka 
wystąpienia przemijającego ataku niedokrwiennego. (Endokrynol Pol 2015; 66 (3): 214–218)
Słowa kluczowe: adiponektyna; przemijające niedokrwinie mózgu/napad przemijającego niedokrwienia mózgu; grubość błony środkowej  
i wewnętrznej; miażdżyca; profil lipidowy
Introduction
Adiponectin (ADP) has recently been recognised 
an adipocytokine, which is accepted to have anti-
inflammatory and anti-atherogenic effects. It prevents 
atherosclerosis by increasing nitric oxide, preventing 
endothelial dysfunction, and by local inhibition of 
inflammatory molecules [1]. Therefore, it has been 
thought to have a protective role in the development 
of ischaemic stroke. This effect has been shown in 
an experimental cerebral ischaemic stroke model [2]. 
However, clinical investigations are associated with 
conflicting results. This contrast may be related with 
the heterogeneity of ischaemic stroke [3]. 
Transient ischaemic attack (TIA) is defined as an 
acute loss of focal cerebral or ocular function with 
symptoms lasting < 24 hours. Previous studies measur-
ing ADP levels were performed mainly in patients with 
cerebral ischaemic events but not TIA. 
The aim of this study was to elucidate a predictive 
value of ADP in patients with TIA. We also evaluated 
the correlation between ADP levels and traditional 
stroke risks factors.
Material and methods
Study subjects
Forty patients with a diagnosis of TIA were included 
into the study. TIA was defined as an acute focal neu-
rologic deficit lasting less than 24 hours. We excluded 
patients with TIA from a non-atherosclerotic source 
such as atrial fibrillation or prosthetic valves. Patients 
with chronic renal or hepatic failure, malignancy, 
recent infection, surgery, and major trauma were 
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Laboratory Medicine Inc., Brno, Czech Republic) ac-
cording to the manufacturer ’s instructions. Both the 
intra- and inter-assay coefficients of variation were 
below 10%. 
Statistical analysis
In statistical analysis the SSPE 16.00 package was used. 
Data were expressed as mean ± standard deviation. 
The normal distribution of the data was confirmed with 
Levene’s Test for Equality of Variances. Analysis of the 
significance of differences between the patients and the 
control group was performed with the Student’s t-test. 
Association between parameters was examined with the 
use of Pearson correlations. All tests were considered 
statistically significant at a p value < 0.05. 
Results
Patient’s characteristics
The clinical and laboratory findings of study probands 
are summarised in Table I. The rates of risk factors re-
lated with TIA are given in Table II. In the control group 
there were no smokers. The number of people with 
HT (70%, 15%), DM (27.5%, 20%), and dyslipidaemia 
(72.5%, 45%) in the patient group were higher than in 
not included into the study. Twenty subjects without 
previous history of TIA or stroke were included into 
the study as a control group. Age and sex distribu-
tion was similar in both groups (p = 0.225 and 0.563, 
respectively). Subjects in the control group had no 
previous stroke.
Patients and healthy subjects were assessed ac-
cording to a protocol that included demographic data, 
medical history, and traditional stroke risk factors. 
Subjects who reported daily smoking were classified 
as ‘smokers’. Blood pressures were measured after 
five minutes of rest. Patients taking antihypertensive 
medications and/or patients with systolic/diastolic 
blood pressure of ≥ 140/90 mm Hg were defined as 
hypertensive [1, 3]. Height and weight were measured, 
and body mass index (BMI) was calculated as weight (in 
kilograms) divided by height (in metres) squared. A BMI 
of less than 25 was accepted as normal [4]. Waist and 
hip circumferences were measured and waist-to-hip 
ratios (WHR) were calculated. A value greater than 0.8 
for a female and more than 1 for a male was accepted 
as abnormal [5]. 
In all study groups, glucose, blood haemoglobin 
A1c (HgA1c), insulin, C-reactive protein (CRP), blood 
urea nitrogen, creatinine, total cholesterol, high density 
lipoprotein cholesterol (HDL), low density lipoprotein 
cholesterol (LDL), very low density lipoprotein cho-
lesterol (VLDL), and triglyceride concentrations were 
measured after a minimum of 12 hours of night fasting, 
by routine laboratory methods. A history of diabetes 
mellitus (DM) and/or ≥ 126 mg/L fasting [3] plasma 
glucose level were defined as DM. Dyslipidaemia was 
defined as a total cholesterol level ≥ 200 mg/dL and/or 
a triglyceride level ≥ 150 mg/dL [6] and/or having 
received treatment for dyslipidaemia. Brain magnetic 
resonance imaging (MRI), and Doppler ultrasonogra-
phy for carotid and vertebral arteries, were evaluated 
in all subjects. In Doppler ultrasonography, internal 
carotid artery intima-media thickness (cIMT) was meas-
ured on both sides. The measurements were made at 
the proximal part of the internal carotid artery, which 
was not seen plaque and stenosis by B mode images. 
The maximal cIMT was recorded at each of the vessel 
segments, and mean values of left and right arteries 
were used in the statistical analyses [7]. A cIMT of less 
than 1 mm was accepted as normal [8].
Analysis of ADP
Plasma samples were taken in the morning after fast-
ing for a minimum of 12 hours. Samples drawn from 
an antecubital vein were quickly transferred into 
glass tubes and centrifuged at 3500 rpm for 5 minutes. 
Samples were kept at –80°C for subsequent assay. ADP 
serum levels were determined by ELISA (BioVendor 
Table I. Demographic, clinical, and laboratory characteristics 
of both groups
Tabela I. Cechy demograficzne, kliniczne oraz laboratoryjne 
obu grup
Parameter Patients (n:40) 
Mean ± SD
Control (n:20) 
Mean ± SD
Female/male 12/28 8/12
Age (years) 64.53 ± 10.51 65.35 ± 8.33 
Body mass index [kg/m2] 26 ± 4 28 ± 4
Waist/hip ratio 0.91 ± 0.06 0.89 ± 0.06
Fasting glucose [mg/L] 101.60 ± 35.59 112.45 ± 32.47
İnsulin [mol/L] 8.10 ± 6.53 11.46 ± 4.67
Haemoglobin A1c (%) 6.28 ± 1.54 5.97 ± 1.01
Total cholesterol [mg/dL] 208.88 ± 42.28 194.55 ± 38.02
High density lipoprotein [mg/dL] 43.00 ± 14.62 43.75 ± 13.17
Low density lipoprotein [mg/dL] 134.40 ± 40.46 124.70 ± 30.08
Very low density lipoprotein [mg/dL] 32.08 ± 17.98 27.15 ± 13.23
Triglyceride [mg/dL] 158.73 ± 89.99 134.80 ± 66.27
C-reactive protein [ng/mL] 0.82 ± 1.30 0.40 ± 0.36
Blood urea nitrogen 39.35 ± 13.08 34.70 ± 10.57
Creatinine [µmol/L] 1.10 ± 0.27 0.98 ± 0.18
Carotid artery intima-media 
thickness [mm]
0.91 ± 0.23 0.79 ± 0.29
Adiponectin [µg/mL] 11.02 ± 8.48 9.34 ± 6.06
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the control group (Fig. 1). Additionally, the number 
of patients with increased cIMT in the patient group 
(37.5%) were higher than in the control group (25%). 
In cranial MRI, acute/subacute ischaemic lesions were 
determined in 13 patients. No abnormality was seen 
in the cranial MRIs of all subjects in the control group. 
ADP levels and cerebrovascular risk factors 
The mean ADP level was found as 11 µg/mL in patients 
group and 9.3 µg/mL in control group. No difference 
was found in terms of ADP levels between the groups 
(p = 0.433). The relationship between the ADP levels 
and other parameters is summarised in Table III. In all 
group analysis, no statistically significant difference was 
found between the ADP level and the other parameters 
except for age (p = 0.027, r = 0.286). There was a trend 
between the ADP levels and sex (p = 0.060, r = –0.244), 
HDL (p = 0.059, r = 0.245) and WHR (p = 0.066, r = 
–0.239). But these differences did not reach statistical 
significance. 
In the patient group, no association was found be-
tween the presence of acute/subacute ischaemic lesion 
on MRI and ADP level (p = 0.195).
Table II. Traditional risk factors in all subjects
Tabela II. Typowe czynniki ryzyka wśród wszystkich 
badanych
Parameter Patients n (%) Control n (%)
Smoking 25 62.5 0 0
Hypertension 28 70 3 15
Diabetes mellitus 11 27.5 4 20
High density lipoprotein  
(male < 40 female < 50)
25 62.5 12 60
Low density lipoprotein (≥ 130) 20 50 6 30
Triglyceride (≥ 150) 17 42.5 6 30
Total cholesterol (≥ 200) 25 62.5 7 35
Dyslipidaemia 29 72.5 9 45
C reactive protein (> 0.8) 11 27.5 5 25
Carotid artery intima-media thickness (≥ 1) 15 37.5 5 25
Waist-hip ratio (female ≥ 0.8 male ≥ 1) 12 30 7 35
Body mass index (≥ 25) 27 67.5 16 80
Figure 1. The risk factors of ischaemic stroke in patients and control group
Rycina 1. Czynniki ryzyka udaru niedokrwiennego wśród pacjentów oraz w grupie kontrolnej
Table III. Correlation analysis of adiponectin levels of all 
subjects with other parameters
Tabela III. Analiza korelacji stężenia adiponektyny 
u wszystkich badanych z innymi parametrami
Parameter Adiponectin
r p
Sex –0.244 0.060
Age 0.286 0.027
Body mass index –0.060 0.647
Waist/hip ratio –0.239 0.066
Fasting glucose –0.006 0.961
İnsulin –0.128 0.328
Total cholesterol –0.092 0.486
High density lipoprotein 0.245 0.059
Low density lipoprotein –0.112 0.395
Very low density lipoprotein –0.192 0.142
Triglyceride –0.212 0.104
Systolic blood pressure –0.087 0.510
Diastolic blood pressure –0.166 0.206
C reactive protein –0.042 0.751
Blood urea nitrogen –0.109 0.409
Creatinine –0.185 0.157
Carotid artery intima-media thickness 0.221 0.090
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Discussion
The role of ADP in the development of ischaemic stroke 
is controversial. Previously, clinical studies have found 
a negative [9–15], a positive [16, 17], or no association 
[18–22] between ischaemic stroke and ADP level. 
A systematic review and meta-analysis of 16 prospec-
tive studies also reported that the ADP level was not 
related to the risk of ischaemic stroke [23]. However, 
Hao et al. concluded, in a meta-analysis including 17 
prospective studies, that higher ADP was associated 
with an increased risk of ischaemic stroke [24]. We found 
that the ADP level was no different in patients with TIA 
than in healthy persons. 
Various hypotheses have been proposed to elucidate 
this controversial issue. One explanation for the dis-
crepancy between studies may be a reduction of ADP 
clearance in renal dysfunction [16, 25]. However, we 
did not find a correlation between ADP levels and renal 
functions. Otherwise, ADP levels might change due to 
the influence of stroke severity and stroke subtypes. The 
patient groups in the studies were not homogenous 
in terms of stroke severity and stroke subtypes. It was 
reported that ADP knockout mice displayed increased 
cerebral infarction size [2]. Also, some clinical studies 
have suggested a negative correlation among ADP 
levels and infarct size or stroke severity [11, 20], but 
not others [9, 26]. In our study no difference was found 
in terms of ADP values between patients and control 
group subjects. On the other hand, sex may affect 
the ADP levels [23]. But we did not find a correlation 
between ADP and sex. Similarly, Kantarova et al. did 
not find an association of ADP levels with sex in acute 
stroke patients [12]. In addition, this conflicting result 
may be explained by allelic heterogeneity. Perhaps the 
genetic variations in the ADP gene contribute to these 
findings [27]. 
An association among ADP levels and traditional 
risk factor of ischaemic stroke, such as triglyceride, 
total cholesterol, HDL, LDL, DM, HT, and obesity, also 
remains unclear. In our study, ADP levels correlated 
positively only with age, as seen in previous studies 
in which ADP levels were found to be correlated with 
age as well as HDL and sex [15, 20, 28]. We noted 
a trend between the ADP levels and HDL and WHR. 
However, the differences did not reach statistical 
significance. We also investigated the association of 
ADP levels with cIMT. Enhanced cIMT is a marker 
for atherosclerosis and is predictive of future stroke. 
Since ADP has antiatherogenic effects, an inverse 
relation between cIMT and ADP levels might be 
expected. In fact, some authors have reported 
a negative correlation [7, 29]. Nonetheless, we did 
not find a correlation between ADP levels with cIMT. 
Ingleseder et al. reported a negative association of 
ADP levels and cIMT, whereas no relationship with 
the presence of atherosclerotic plaques in healthy 
volunteers was seen [7]. In our study, no difference 
was found between ADP levels and the presence of 
atherosclerotic plaques. 
 There are some weak points to our study. Firstly, 
we measured only the total amount of ADP. The high 
molecular weight ADP (HWM) is a major bioactive 
form with respect to endothelial function [19]. In post-
menopausal women, Ogorodnikova et al. found no evi-
dence of an association between high molecular weight 
adiponectin levels and ischaemic stroke [19]. Secondly, 
several medications may affect ADP levels [30, 31], 
but we could not pay attention to drug use. Another 
limitation of the study was the small sample size.
In conclusion, our results suggest that ADP level 
does not correlate with transient ischaemic stroke. 
We think that ADP is not a predictive risk factor of 
TIA. Further studies should be performed with larger 
sample sizes. 
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